Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MOVe-AHEAD trial

- PMLiVE

UK trial evaluating mixed-vaccine regimens includes two more jabs

Results from the first stage of the Com-Cov trial are expected next month

- PMLiVE

Moderna’s booster vaccine for South African variant demonstrates promising early results

Booster vaccine candidate increase neutralising titers against SARS-CoV-2 variants of concern in preclinical study

- PMLiVE

J&J delays EU COVID-19 vaccine rollout following pause in the US

FDA and CDC recommended pausing rollout in US after reported cases of rare blood clots in vaccinated individuals

- PMLiVE

UPDATE: US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots

An advisory committee to the CDC recommended extending the pause in the US to review additional data

- PMLiVE

Oxford study finds standard asthma medication improves recovery time in COVID-19 patients

Early treatment with inhaled budesonide could help high-risk patients

- PMLiVE

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

MHRA is looking "very closely" at reports of adverse reactions to coronavirus vaccines

- PMLiVE

Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk

REGEN-COV reduced the risk of symptomatic infections by 81% in a phase 3 prevention trial

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives...

Impetus Digital

- PMLiVE

CanSinoBIO considers booster jab for COVID-19 vaccine

Chinese biotech company said the efficacy rate for the one-dose vaccine could decrease over time

- PMLiVE

New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement

Regulators in Canada and Germany have reportedly placed new restrictions on vaccine

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine is 100% effective in adolescents

Vaccine was found to be safe and effective in adolescents aged 12 to 15 years old

- PMLiVE

BioNTech forecasts €9.8bn in sales of Pfizer-partnered COVID-19 vaccine in 2021

Company also raised full year manufacturing capacity target for vaccine to 2.5 billion doses

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links